Table 4. LENT SOMA subscale scores at each assessment.
Pre-treatment | Immediately after-treatment | 6 weeks | 12 months | 24 months | 36 months | |
---|---|---|---|---|---|---|
EORTC QLQ-C30 symptom scales | ||||||
Uterus/ Cervix | ||||||
Mean | 0.64 | 0.71 | 0.49 | 0.54 | 0.48* | 0.54 |
Median | 0.75 | 0 | 0 | 0 | 0* | 0.5 |
LQ–UQ | 0.75–1.25 | 0–1.25 | 0–1.00 | 0–0.75 | 0–0.75 | 0–0.75 |
Ovary/Reproductive | ||||||
Mean | 0.67 | 0.71 | 1.12* | 0.82 | 0.79 | 0.72 |
Median | 0 | 0 | 2* | 0 | 0 | 0 |
LQ–UQ | 0–0 | 0–1 | 0–2 | 0–1 | 0–2 | 0–1 |
Rectum/ Bowel | ||||||
Mean | 0.19 | 0.53** | 0.19** | 0.32** | 0.31** | 0.29** |
Median | 0 | 0.62** | 0.07** | 0.21** | 0.21** | 0.14** |
LQ–UQ | 0–0.07 | 0.21–1.15 | 0–0.29 | 0.07–0.31 | 0.14–0.36 | 0–0.29 |
Bladder/ Urethra | ||||||
Mean | 0.49 | 0.66** | 0.56 | 0.52 | 0.59 | 0.59* |
Median | 0.29 | 0.43** | 0.43 | 0.43 | 0.33 | 0.71* |
LQ–UQ | 0.14–0.43 | 0.14–1.00 | 0.14–0.57 | 0.14–1.00 | 0.14–0.71 | 0.14–1.14 |
Ureter/ Kidney | ||||||
Mean | 0.21 | 0.30 | 0.37* | 0.45* | 0.45* | 0.50* |
Median | 0 | 0 | 0* | 1* | 0* | 1* |
LQ–UQ | 0–0 | 0–0 | 0–1 | 0–1 | 0–1 | 0–1 |
Vagina/sexual function | ||||||
Mean | 0.65 | 0.65 | 0.72* | 0.65 | 0.68 | 0.66 |
Median | 0.57 | 0.57 | 0.56* | 0.57 | 0.57 | 0.67 |
LQ–UQ | 0.50–0.57 | 0.57–0.57 | 0.43–0.67 | 0.30–0.67 | 0.33–0.71 | 0.50–0.80 |
Pain | ||||||
Mean | 0.48 | 0.71** | 0.37 | 0.46 | 0.48 | 0.48 |
Median | 0.25 | 0.5** | 0.5 | 0.25 | 0 | 0.25 |
LQ–UQ | 0–0.50 | 0–1.14 | 0–0.75 | 0–0.71 | 0–0.43 | 0–0.43 |
Overall LENT SOMA score | ||||||
Mean | 0.43 | 0.61** | 0.46** | 0.50** | 0.51* | 0.51* |
Median | 0.32 | 0.47** | 0.38** | 0.5** | 0.33* | 0.59* |
LQ–UQ | 0.18–0.38 | 0.44–1.00 | 0.29–0.68 | 0.29–0.66 | 0.30–0.53 | 0.29–0.63 |
EORTC=European Organisation for the Research and Treatment of Cancer; LENT SOMA=Late Effects Normal Tissues (LENT) – Subjective Objective Management Analysis; LQ–UQ=Lower quartile – upper quartile.
*P<0.01 vs pre-treatment.
**P<0.001 vs pre-treatment.